CA2483028C - Diffusion-controlled dosage form and method of fabrication including three dimensional printing - Google Patents
Diffusion-controlled dosage form and method of fabrication including three dimensional printing Download PDFInfo
- Publication number
- CA2483028C CA2483028C CA2483028A CA2483028A CA2483028C CA 2483028 C CA2483028 C CA 2483028C CA 2483028 A CA2483028 A CA 2483028A CA 2483028 A CA2483028 A CA 2483028A CA 2483028 C CA2483028 C CA 2483028C
- Authority
- CA
- Canada
- Prior art keywords
- dosage form
- release
- shell
- polymer
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 281
- 238000009792 diffusion process Methods 0.000 title claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 45
- 238000010146 3D printing Methods 0.000 title claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 215
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 209
- 239000000843 powder Substances 0.000 claims abstract description 124
- 239000002245 particle Substances 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 74
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 239000000872 buffer Substances 0.000 claims abstract description 46
- 239000007788 liquid Substances 0.000 claims description 191
- 239000011230 binding agent Substances 0.000 claims description 99
- 239000004014 plasticizer Substances 0.000 claims description 72
- 239000000126 substance Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 31
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 30
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 28
- 230000009477 glass transition Effects 0.000 claims description 25
- 238000000151 deposition Methods 0.000 claims description 22
- 239000011800 void material Substances 0.000 claims description 21
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 19
- 230000007547 defect Effects 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 15
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 15
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000011118 polyvinyl acetate Substances 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 230000008021 deposition Effects 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 3
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003556 aminophylline Drugs 0.000 claims description 3
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims description 3
- 229960003108 brompheniramine maleate Drugs 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- SRGKFVAASLQVBO-DASCVMRKSA-N dexbrompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 SRGKFVAASLQVBO-DASCVMRKSA-N 0.000 claims description 3
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001687 orphenadrine citrate Drugs 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- -1 poly(vinyl acetate) Polymers 0.000 claims 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 230000003685 thermal hair damage Effects 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010072064 Exposure to body fluid Diseases 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 238000005304 joining Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000011257 shell material Substances 0.000 description 198
- 238000009472 formulation Methods 0.000 description 47
- 238000012360 testing method Methods 0.000 description 44
- 239000010410 layer Substances 0.000 description 42
- 238000004090 dissolution Methods 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 23
- 239000012530 fluid Substances 0.000 description 21
- 238000007639 printing Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 18
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 14
- 230000004888 barrier function Effects 0.000 description 14
- 229920003134 Eudragit® polymer Polymers 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 239000012738 dissolution medium Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000007480 spreading Effects 0.000 description 5
- 238000003892 spreading Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 229960003908 pseudoephedrine Drugs 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000009506 drug dissolution testing Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000000203 droplet dispensing Methods 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940089453 sudafed Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000013064 process characterization Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/141—Processes of additive manufacturing using only solid materials
- B29C64/153—Processes of additive manufacturing using only solid materials using layers of powder being selectively joined, e.g. by selective laser sintering or melting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37844902P | 2002-05-06 | 2002-05-06 | |
| US60/378,449 | 2002-05-06 | ||
| US42509402P | 2002-11-08 | 2002-11-08 | |
| US60/425,094 | 2002-11-08 | ||
| PCT/US2003/014376 WO2003092633A2 (en) | 2002-05-06 | 2003-05-06 | Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2483028A1 CA2483028A1 (en) | 2003-11-13 |
| CA2483028C true CA2483028C (en) | 2011-04-05 |
Family
ID=29406838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2483028A Expired - Lifetime CA2483028C (en) | 2002-05-06 | 2003-05-06 | Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8088415B2 (enExample) |
| EP (1) | EP1503741B1 (enExample) |
| JP (1) | JP5041663B2 (enExample) |
| AT (1) | ATE407665T1 (enExample) |
| AU (1) | AU2003232078A1 (enExample) |
| CA (1) | CA2483028C (enExample) |
| DE (1) | DE60323482D1 (enExample) |
| ES (1) | ES2316791T3 (enExample) |
| WO (1) | WO2003092633A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177636A (zh) * | 2016-11-15 | 2019-08-27 | 霍加纳斯股份有限公司 | 用于增材制造法的原料、使用其的增材制造法和由其获得的制品 |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1503741B1 (en) | 2002-05-06 | 2008-09-10 | Massachusetts Institute Of Technology | Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| CN1897924B (zh) * | 2003-09-26 | 2011-09-21 | 阿尔扎公司 | 能提供高载药量的药物包衣和提供它的方法 |
| US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
| US8101244B2 (en) * | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
| TWI428271B (zh) * | 2004-06-09 | 2014-03-01 | Smithkline Beecham Corp | 生產藥物之裝置及方法 |
| WO2006004069A1 (ja) * | 2004-07-01 | 2006-01-12 | Ngk Insulators, Ltd. | 微小カプセルおよびその製造方法 |
| EP2131817A2 (en) * | 2007-03-09 | 2009-12-16 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
| WO2009085832A2 (en) * | 2007-12-21 | 2009-07-09 | Mcneil-Ppc, Inc. | Manufacture of tablet |
| CN101716162B (zh) * | 2009-11-26 | 2012-11-14 | 扬州中宝制药有限公司 | 一种氨茶碱缓释胶囊及其制备方法 |
| US8251837B2 (en) * | 2010-08-11 | 2012-08-28 | Nike, Inc. | Floating golf ball |
| WO2012080833A2 (en) | 2010-12-13 | 2012-06-21 | Purdue Pharma L.P. | Controlled release dosage forms |
| US9381154B2 (en) * | 2011-06-09 | 2016-07-05 | Xerox Corporation | Direct inkjet fabrication of drug delivery devices |
| EP3842215B1 (en) | 2012-09-05 | 2023-11-22 | Aprecia Pharmaceuticals LLC | Three-dimensional printing system and equipment assembly |
| US8888480B2 (en) | 2012-09-05 | 2014-11-18 | Aprecia Pharmaceuticals Company | Three-dimensional printing system and equipment assembly |
| US20140099351A1 (en) * | 2012-10-04 | 2014-04-10 | Axxia Pharmaceuticals, Llc | Process for making controlled release medical implant products |
| CN109908355B (zh) | 2013-03-15 | 2022-11-15 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散剂型 |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| JP6233996B2 (ja) | 2013-08-16 | 2017-11-22 | ザ エクスワン カンパニー | ３次元印刷される金属鋳造用鋳型及び同鋳型の製造方法 |
| WO2015057761A1 (en) | 2013-10-17 | 2015-04-23 | The Exone Company | Three-dimensional printed hot isostatic pressing containers and processes for making same |
| EP2875933B1 (de) * | 2013-11-25 | 2019-04-03 | MTU Aero Engines GmbH | Dokumentation generativer Herstellungsverfahren |
| MX2016007786A (es) | 2013-12-16 | 2017-03-03 | Massachusetts Inst Technology | Formulaciones de sal de micronutrientes fortificadas. |
| EP3763383A1 (en) * | 2013-12-16 | 2021-01-13 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
| US20160332373A1 (en) | 2013-12-23 | 2016-11-17 | The Exone Company | Methods and Systems for Three-Dimensional Printing Utilizing Multiple Binder Fluids |
| WO2015100084A1 (en) | 2013-12-23 | 2015-07-02 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
| IL232696B (en) | 2014-05-19 | 2018-08-30 | Technion Res & Dev Foundation | Compound and method for detecting molecules of interest |
| US20170120329A1 (en) | 2014-05-29 | 2017-05-04 | The Exone Company | Process for Making Nickel-Based Superalloy Articles by Three-Dimensional Printing |
| EP3169499A2 (en) | 2014-07-17 | 2017-05-24 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
| US11771655B2 (en) | 2014-09-08 | 2023-10-03 | University Of Central Lancashire | Solid dosage form production |
| US9844930B2 (en) | 2014-11-05 | 2017-12-19 | Xerox Corporation | 3D printing of digestible shells for medicaments |
| US20180001551A1 (en) | 2014-12-03 | 2018-01-04 | The Exone Company | Process for Making Densified Carbon Articles by Three Dimensional Printing |
| AU2016272089B2 (en) * | 2015-06-03 | 2021-02-18 | Triastek, Inc. | Dosage forms and use thereof |
| CN113171350B (zh) * | 2015-06-03 | 2023-05-26 | 南京三迭纪医药科技有限公司 | 药品剂型及其使用 |
| US20180214383A1 (en) * | 2015-07-16 | 2018-08-02 | National University Of Singapore | Printing drug tablets with fully customizable release profiles for personalized medicine |
| CA2996041A1 (en) | 2015-08-21 | 2017-03-02 | Aprecia Pharmaceuticals LLC | Three-dimensional printing system and equipment assembly |
| GB201519128D0 (en) * | 2015-10-29 | 2015-12-16 | Univ Central Lancashire | Solid forms and methods of preparing the same |
| CA3023278C (en) | 2016-05-05 | 2019-04-30 | Triastek, Inc. | Controlled release dosage form |
| US12303603B2 (en) * | 2016-06-20 | 2025-05-20 | Sciperio, Inc | Real-time compounding 3D printer |
| US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
| GB201612853D0 (en) | 2016-07-25 | 2016-09-07 | Univ Central Lancashire | Solid dosage form production |
| DE102017200773A1 (de) | 2017-01-18 | 2018-07-19 | Eos Gmbh Electro Optical Systems | Verfahren zum Nachbehandeln und Nachbehandlungssytem |
| JP7191385B2 (ja) * | 2017-01-26 | 2022-12-19 | トリアステック インコーポレイテッド | 特定の胃腸部位での制御放出の剤形 |
| US10369557B2 (en) | 2017-04-12 | 2019-08-06 | International Business Machines Corporation | Three-dimensional printed objects for chemical reaction control |
| WO2018199998A1 (en) * | 2017-04-28 | 2018-11-01 | Hewlett-Packard Development Company, L.P. | Producing diffusion-controlled release devices |
| WO2019025869A1 (en) * | 2017-07-31 | 2019-02-07 | Teva Pharmaceutical Industries Limited | GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER |
| US11642841B2 (en) | 2017-10-13 | 2023-05-09 | Ut-Battelle, Llc | Indirect additive manufacturing process |
| US10350822B1 (en) * | 2018-01-09 | 2019-07-16 | Triastek Inc. | Dosage forms with desired release profiles and methods of designing and making thereof |
| CN111698983B (zh) | 2018-01-09 | 2022-10-18 | 南京三迭纪医药科技有限公司 | 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型 |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| DE102018107585B3 (de) * | 2018-03-29 | 2019-03-28 | Universität Rostock | Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen |
| WO2019199328A1 (en) * | 2018-04-13 | 2019-10-17 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| CN108939162B (zh) * | 2018-07-10 | 2021-11-19 | 上海理工大学 | 一种介孔生物玻璃/海藻酸钠-海藻酸钠分层骨组织工程支架的制备方法 |
| GB201813186D0 (en) | 2018-08-13 | 2018-09-26 | Univ Central Lancashire | Solid dosage from production |
| AU2019337800A1 (en) * | 2018-09-14 | 2021-05-13 | Merck Patent Gmbh | Process for the preparation of a coated solid pharmaceutical dosage form |
| JP7614103B2 (ja) | 2018-10-15 | 2025-01-15 | アプレシア・ファーマスーティカルズ・エルエルシー | 包装内に剤形を形成する方法およびシステム |
| US11254617B2 (en) | 2019-01-09 | 2022-02-22 | Ut-Battelle, Llc | Indirect additive manufacturing process using amine-containing adhesive polymers |
| US12103229B2 (en) * | 2019-03-15 | 2024-10-01 | Ricoh Company, Ltd. | Jettable temporary binders to create removable support materials |
| US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
| WO2021028355A1 (en) * | 2019-08-14 | 2021-02-18 | Merck Patent Gmbh | Method for additive manufacture of a product, manufacturing device and solid pharmaceutical dosage form |
| GB201913972D0 (en) | 2019-09-27 | 2019-11-13 | Univ Ulster | Pharmaceutical Delivery Device and method of manufacture |
| ES2828509B2 (es) | 2019-11-26 | 2022-03-09 | Fund Idonial | Composicion para la impresion 3d de farmacos semisolidos |
| EP3871859A1 (en) * | 2020-02-26 | 2021-09-01 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| WO2021176361A1 (en) * | 2020-03-02 | 2021-09-10 | Craft Health Pte Ltd | Method of manufacturing oral dosage forms for extended drug release |
| CA3178260A1 (en) | 2020-05-13 | 2021-11-18 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
| WO2021263132A1 (en) | 2020-06-26 | 2021-12-30 | Aprecia Pharmaceuticals LLC | Rapidly-orodispersible tablets having an interior cavity |
| JP2023550274A (ja) | 2020-10-30 | 2023-12-01 | トリアステック インコーポレイテッド | 胃滞留型医薬剤形 |
| US12251208B2 (en) | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| KR102723494B1 (ko) * | 2020-12-24 | 2024-10-31 | 동아제약 주식회사 | 적층 방식으로 제조된 방출 조절용 약제학적 조성물 |
| CN112940690B (zh) * | 2021-02-05 | 2021-11-02 | 中国科学院苏州纳米技术与纳米仿生研究所南昌研究院 | 一种具有豆荚结构的相变储能材料及其制备方法与应用 |
| EP4618958A1 (en) * | 2022-11-18 | 2025-09-24 | Aprecia Pharmaceuticals LLC | Functionally-dividable orodispersive dosage form |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US948297A (en) * | 1909-07-24 | 1910-02-01 | John A Stone | Corn-husker. |
| US986148A (en) * | 1910-05-09 | 1911-03-07 | Hoechst Ag | Derivative of oxyarylarsinic acids and process of making same. |
| ZA822995B (en) * | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
| JPH0759499B2 (ja) * | 1984-02-10 | 1995-06-28 | ベンツォン ファーマ エイ／エス | 拡散被覆された複合単位服用剤 |
| US4810502A (en) * | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5204055A (en) * | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
| NZ242065A (en) * | 1991-03-26 | 1996-06-25 | Csl Ltd | Delayed release implant having a degradable or rupturable polymeric coating |
| US5490882A (en) * | 1992-11-30 | 1996-02-13 | Massachusetts Institute Of Technology | Process for removing loose powder particles from interior passages of a body |
| US5775402A (en) * | 1995-10-31 | 1998-07-07 | Massachusetts Institute Of Technology | Enhancement of thermal properties of tooling made by solid free form fabrication techniques |
| US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
| US6280771B1 (en) * | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
| US6238704B1 (en) * | 1996-09-13 | 2001-05-29 | Shionogi & Co., Ltd. | Sustained-release preparation utilizing thermal change and process for the production thereof |
| WO1998036738A1 (en) * | 1997-02-20 | 1998-08-27 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| US6213168B1 (en) * | 1997-03-31 | 2001-04-10 | Therics, Inc. | Apparatus and method for dispensing of powders |
| EP1015153A4 (en) * | 1997-03-31 | 2004-09-01 | Therics Inc | POWDER DISPENSING PROCESS |
| US6547994B1 (en) * | 1998-11-13 | 2003-04-15 | Therics, Inc. | Rapid prototyping and manufacturing process |
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| DE19961897A1 (de) * | 1999-12-20 | 2001-06-28 | Basf Ag | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
| DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
| DE60116758T2 (de) | 2000-05-18 | 2006-11-02 | Therics, Inc. | Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform |
| WO2002038280A2 (en) * | 2000-11-10 | 2002-05-16 | Therics, Inc. | A wetting-resistant nozzle for dispensing small volumes of liquid and a method for manufacturing a wetting-resistant nozzle |
| EP1503741B1 (en) | 2002-05-06 | 2008-09-10 | Massachusetts Institute Of Technology | Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| US20050015728A1 (en) * | 2003-07-17 | 2005-01-20 | International Business Machines Corporation | Method, system, and program product for customizing a user interface |
-
2003
- 2003-05-06 EP EP03747680A patent/EP1503741B1/en not_active Expired - Lifetime
- 2003-05-06 AT AT03747680T patent/ATE407665T1/de not_active IP Right Cessation
- 2003-05-06 US US10/431,353 patent/US8088415B2/en active Active
- 2003-05-06 DE DE60323482T patent/DE60323482D1/de not_active Expired - Lifetime
- 2003-05-06 CA CA2483028A patent/CA2483028C/en not_active Expired - Lifetime
- 2003-05-06 AU AU2003232078A patent/AU2003232078A1/en not_active Abandoned
- 2003-05-06 WO PCT/US2003/014376 patent/WO2003092633A2/en not_active Ceased
- 2003-05-06 ES ES03747680T patent/ES2316791T3/es not_active Expired - Lifetime
- 2003-05-06 JP JP2004500818A patent/JP5041663B2/ja not_active Expired - Lifetime
-
2011
- 2011-11-29 US US13/306,393 patent/US8465777B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177636A (zh) * | 2016-11-15 | 2019-08-27 | 霍加纳斯股份有限公司 | 用于增材制造法的原料、使用其的增材制造法和由其获得的制品 |
| CN110177636B (zh) * | 2016-11-15 | 2021-12-21 | 霍加纳斯股份有限公司 | 用于增材制造法的原料、使用其的增材制造法和由其获得的制品 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120177696A1 (en) | 2012-07-12 |
| US20040005360A1 (en) | 2004-01-08 |
| CA2483028A1 (en) | 2003-11-13 |
| WO2003092633A2 (en) | 2003-11-13 |
| DE60323482D1 (de) | 2008-10-23 |
| WO2003092633A3 (en) | 2004-04-08 |
| ATE407665T1 (de) | 2008-09-15 |
| EP1503741B1 (en) | 2008-09-10 |
| JP2005524702A (ja) | 2005-08-18 |
| JP5041663B2 (ja) | 2012-10-03 |
| US8088415B2 (en) | 2012-01-03 |
| EP1503741A2 (en) | 2005-02-09 |
| ES2316791T3 (es) | 2009-04-16 |
| US8465777B2 (en) | 2013-06-18 |
| AU2003232078A1 (en) | 2003-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2483028C (en) | Diffusion-controlled dosage form and method of fabrication including three dimensional printing | |
| CA2408956C (en) | Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form | |
| Conte et al. | Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility | |
| FI121620B (fi) | Menetelmiä aktiivisen aineen kontrolloidusti vapautuvan formulaation saamiseksi | |
| EP1267842B1 (en) | Method for producing a controlled-release tablet using a pore forming agent in the coating | |
| Murthy et al. | Current perspectives on the dissolution stability of solid oral dosage forms | |
| US5830503A (en) | Enteric coated diltiazem once-a-day formulation | |
| HRP960554A2 (en) | Pharmaceutical formulations | |
| DK2303020T3 (en) | Preparation of Skeletal Muscle Relaxing Dosage Forms with Controlled Release | |
| JPH0269414A (ja) | 持続的制御放出パターンを有する生物活性物質コーティング剤 | |
| CA2448558A1 (en) | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery | |
| Macchi et al. | Enteric-coating of pulsatile-release HPC capsules prepared by injection molding | |
| WO2011039686A1 (en) | Latrepirdine oral sustained release dosage forms | |
| US7858119B1 (en) | Extended release pharmaceuticals | |
| JPS6037093B2 (ja) | 被覆組成物 | |
| KR20070000439A (ko) | 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제 | |
| WO2001080824A2 (en) | Dual mechanism timed release dosage forms for low dose drugs | |
| WO2007117110A2 (en) | Sustained-release pellets containing tamsulosin hydrochloride and processes for preparing the same | |
| WO2021014360A1 (en) | Oral modified release dosage forms | |
| Colombo et al. | Swellable and rigid matrices: controlled release matrices with cellulose ethers | |
| Wen et al. | Oral extended release hydrophilic matrices: formulation and design | |
| JPH06190267A (ja) | マイクロカプセル | |
| Jadhav et al. | EXTENDED RELEASE PELLETS: NOVEL APPROACH TO TARGETED DRUG DELIVERY SYSTEM | |
| Pai et al. | Multiple Unit Particle System (MUPS): Novel technology for preparation of Extended Release (ER) tablets | |
| HK40032807A (en) | Tofacitinib oral sustained release dosage forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20230508 |